Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience - Wikidata - awgldk - TriplyDB

Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience

Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience

http://www.wikidata.org/entity/Q33389392

about

Atypical hemolytic uremic syndrome Clinical Practice Guidelines for the Management of Atypical Hemolytic Uremic Syndrome in Korea Advances and challenges in the management of complement-mediated thrombotic microangiopathies Clinical evaluation of thrombotic microangiopathy: identification of patients with suspected atypical hemolytic uremic syndrome Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue.Novel developments in thrombotic microangiopathies: is there a common link between hemolytic uremic syndrome and thrombotic thrombocytic purpura?A Case of Thrombotic Thrombocytopenia Purpura Associated with Systemic Lupus Erythematosus: Diagnostic Utility of ADAMTS-13 Activity.Splenectomy and/or cyclophosphamide as salvage therapies in thrombotic thrombocytopenic purpura: the French TMA Reference Center experience.Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpura.Development and validation of a predictive model for death in acquired severe ADAMTS13 deficiency-associated idiopathic thrombotic thrombocytopenic purpura: the French TMA Reference Center experience.Thrombotic microangiopathy and associated renal disorders.Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies.Complement factor H-related protein 1 deficiency and factor H antibodies in pediatric patients with atypical hemolytic uremic syndrome.High prevalence of infectious events in thrombotic thrombocytopenic purpura and genetic relationship with toll-like receptor 9 polymorphisms: experience of the French Thrombotic Microangiopathies Reference Center.Measurement and prevalence of circulating ADAMTS13-specific immune complexes in autoimmune thrombotic thrombocytopenic purpura.How I treat thrombotic thrombocytopenic purpura and atypical haemolytic uraemic syndrome Diagnostic and prognostic values of ADAMTS13 activity measured during daily plasma exchange therapy in patients with acquired thrombotic thrombocytopenic purpura.How we approach an acquired thrombotic thrombocytopenic purpura patient.Postpartum thrombotic microangiopathy revealed as atypical hemolytic uremic syndrome successfully treated with eculizumab: a case report Cardiac troponin-I on diagnosis predicts early death and refractoriness in acquired thrombotic thrombocytopenic purpura. Experience of the French Thrombotic Microangiopathies Reference Center.A phase-II sequential case-series study of all patients presenting to four plasma exchange centres with presumed relapsed/refractory thrombotic thrombocytopenic purpura treated with rituximab.Modified Ham test for atypical hemolytic uremic syndrome Plasma resistant atypical hemolytic uremic syndrome associated with a CFH mutation treated with eculizumab: a case report.Incidence of obstetrical thrombotic thrombocytopenic purpura in a retrospective study within thrombocytopenic pregnant women. A difficult diagnosis and a treatable disease.Type of plasma preparation used for plasma exchange and clinical outcome of adult patients with acquired idiopathic thrombotic thrombocytopenic purpura: a French retrospective multicenter cohort study.Impact of severe ADAMTS13 deficiency on clinical presentation and outcomes in patients with thrombotic microangiopathies: the experience of the Harvard TMA Research Collaborative.The utility of ADAMTS13 in differentiating TTP from other acute thrombotic microangiopathies: results from the UK TTP Registry.The role of ADAMTS-13 activity and complement mutational analysis in differentiating acute thrombotic microangiopathies The thrombotic microangiopathy Registry of North America: A United States multi-institutional TMA network.Twice-daily therapeutical plasma exchange-based salvage therapy in severe autoimmune thrombotic thrombocytopenic purpura: the French TMA Reference Center experience.What's new in the diagnosis and pathophysiology of thrombotic thrombocytopenic purpura.The global aHUS registry: methodology and initial patient characteristics.Exchange transfusion for neonate with haemolytic uremic syndrome.Correlation between ADAMTS13 activity and neurological impairment in acute thrombotic microangiopathy patients.Assessment of endothelial damage and cardiac injury in a mouse model mimicking thrombotic thrombocytopenic purpura.Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.Thrombotic thrombocytopenic purpura misdiagnosed as autoimmune cytopenia: Causes of diagnostic errors and consequence on outcome. Experience of the French thrombotic microangiopathies reference centre.Atypical Hemolytic Uremic Syndrome: A Brief Review.Thrombotic Thrombocytopenic Purpura: Pathogenesis, Diagnosis, and Potential Novel Therapeutics.Predictive features of chronic kidney disease in atypical haemolytic uremic syndrome.

P2860

Q21202864-579FFD44-5661-4C58-91CA-5BD2820B974B Q26739894-4BAA1619-84F3-4B66-A984-3AAA8DFFB232 Q26796453-75956C7F-E2C4-4FD3-9DAC-9ED9A238F69C Q28067041-9F5A6EAC-BACA-40EA-BECD-FE12ECA19336 Q30276550-A057C942-DFD6-4892-BDF6-EE31F2873324 Q33395774-7AA52BDF-C6EF-481D-8B0D-8139340F84BF Q33396306-EBD45D26-4B88-4A51-8D1D-F4B2D7BFBAEA Q33400172-2CA1B1C8-23B2-488A-926B-4AE2298C66AA Q33400891-D1F84AE5-512C-4F47-9001-96AFDA47EEAD Q33401197-71EF9833-66EF-41A7-95BF-67311B289A04 Q33402372-55BFFB37-193F-4F57-9216-C6B50B6E5562 Q33403607-1980F416-3E63-4EA9-8F47-AF535E1DA704 Q33404847-7847463A-44D1-475B-A121-B2D2F55B5BC5 Q33407984-C6EC301C-267A-4B19-9A55-6548263E6E78 Q33412212-D5006A12-9EEA-4FB4-BE00-C65B24E90F8D Q33412445-7EBE4B40-5520-48FD-A9AD-CB922A4F8CC0 Q33416047-9FAF1D98-B7B7-49BC-8147-2A9DA48E414E Q33416780-FAEC5DE8-B5D6-40E1-91E5-3B0AB9E17423 Q33417655-B3FCADD6-6EE6-4739-99EA-4DDE97D6EC30 Q33418732-87E4218D-7C8E-4606-99DB-63473AC144FD Q33421822-5444A46B-75FD-4D93-B76F-5289BCF7A471 Q33421884-913A01ED-4377-40DC-BB02-683344BC2608 Q33422433-7D17E952-E6CF-4032-A77E-C82E5A161BCF Q33423670-0415B239-A482-44E6-B023-0D789CA971B3 Q33424405-A4CD92C8-07CA-4341-9FBA-7A9102FD270F Q33425489-2A55892E-E010-4129-A9A9-FEED8A35AF2A Q33425754-AAE91ECC-07C0-4E10-BB6D-7670EC92512B Q33427495-FD8AA813-B8C3-4EC9-889E-CF833FC84BC5 Q33427586-FFDDA055-618E-44FB-8F2A-82714EB48F21 Q33427885-F3575636-362D-46D3-846D-99C5A4870B4A Q33428178-6803F64A-B5BC-4B58-9AD9-1B14221D9673 Q33428291-70F7CAC7-E6D7-4A83-A630-D3583AD61921 Q33429701-ADAB793C-1F56-45DB-8B50-C3451A734DD7 Q33433636-9981C794-A003-450B-B234-8F86F07B496B Q33434431-5971C636-F0B6-467A-9D08-6EAFD899CC7B Q33436512-986E3394-02C8-4CCB-B234-C63D9FE6B32F Q33438800-9A62B597-5C9B-4B58-89BE-ADEC9F8598B0 Q33442794-B1483799-813D-4239-BB74-06AD70E4205D Q33443111-7F73F49A-1B9C-4CB3-B519-E7564A33E22E Q33704263-B83F35D3-4AEA-4797-907A-BFD0BB197F01

P2860

Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience

http://www.wikidata.org/entity/Q33389392

description

2010 nî lūn-bûn

@nan

2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

name

Predictive features of severe ...... MA reference center experience

@ast

Predictive features of severe ...... MA reference center experience

@en

type

label

Predictive features of severe ...... MA reference center experience

@ast

Predictive features of severe ...... MA reference center experience

@en

prefLabel

Predictive features of severe ...... MA reference center experience

@ast

Predictive features of severe ...... MA reference center experience

@en

P1433

Q33389392-0A74F80D-26A2-419D-91F9-C06FA6C5D5FE

P1476

Q33389392-3877C830-BAEB-4AD8-9225-0937988321F2

P2093

Q33389392-081DA627-7DC4-4B55-9F99-A4BE803EC7D9

Q33389392-1A77C8E7-84A2-48F5-A9EC-D26C8CA1383E

Q33389392-24A9EAB1-9053-460C-B6A9-D50075B790C9

Q33389392-4D1F9858-173B-4EFB-9F27-B8389F7850D8

Q33389392-5CE709A4-AE0E-49CB-9BB1-EF5ACFDA699D

Q33389392-623B07FF-428E-4DCE-8C08-9755A003DE80

Q33389392-6588BD7B-051E-4373-80FB-FD67406A9C72

Q33389392-698E5AE2-9EBE-4371-B713-90C2C5D9590B

Q33389392-72CA241C-DA28-4D20-AC69-69BCED5A060B

Q33389392-73A43813-C10B-4C66-AA35-F71B86126872

P2860

Q33389392-0C34E8D7-EB06-44F3-BF10-AD1F755084AC

Q33389392-0DC4AF9D-6BC2-4417-B2EB-33C956B84AA0

Q33389392-26068660-51A9-423F-9B31-336DE4248F5D

Q33389392-31A82123-BE55-4264-BEE8-221E24A7659B

Q33389392-3EC4329F-E6C6-4C53-99D9-228122F1C1BF

Q33389392-42EE23AD-0276-4AAF-A379-FFB5FD97E9F2

Q33389392-475BF071-EDF7-4CCA-930B-2377BFDD852F

Q33389392-52AB6B3E-1E92-47F6-AA06-D8C7D61308C7

Q33389392-71AB9BF4-4EA4-42EE-84BB-D8226148840C

Q33389392-7947DDD0-74B1-4D1C-8C75-93F5EFCB9A2E

P304

Q33389392-43A98222-6E2A-42CD-BA42-7CE5B5332CD4

P31

Q33389392-81BB427F-8F18-43F0-9193-D6E0137B84D7

P356

Q33389392-24ADE9D6-CE90-4AB2-89D3-EA36D087E6A4

P407

Q33389392-491746C1-1697-46F1-8783-1704A3478089

P433

Q33389392-C1F712E3-B280-46A8-9451-7F8786043C94

P478

Q33389392-17FE8591-8F5D-496B-8A98-F407A0E809F7

P50

Q33389392-2827B129-FA18-46C1-B9E9-BF79B97C66D6

Q33389392-2F28434B-4DF5-4542-AA19-A0B1B607E549

Q33389392-63EC072D-6174-4D29-8C79-EE96F00DB4A5

Q33389392-85264DBD-B342-44C5-8F41-F62F44F97338

P577

Q33389392-C975009D-57F1-4F4C-96BF-A975F76B122E

P5875

Q33389392-AA12A145-4599-4D42-9BB7-0904CFD170B4

P698

Q33389392-D2D6B8C5-E628-42AB-BC70-D538E806BB92

P921

Q33389392-0F54E95A-ACEC-4ABA-83F3-ECC3868FFF0F

P932

Q33389392-283D7164-41B6-4C15-B325-291019772A2B

P356

JOURNAL.PONE.0010208

P1433

P1476

Predictive features of severe ...... MA reference center experience

@en

P2093

Agnès Veyradier

http://www.w3.org/2001/XMLSchema#string

Alain Wynckel

http://www.w3.org/2001/XMLSchema#string

Bertrand Guidet

http://www.w3.org/2001/XMLSchema#string

Christophe Ridel

http://www.w3.org/2001/XMLSchema#string

Claire Presne

http://www.w3.org/2001/XMLSchema#string

Dominique Bordessoule

http://www.w3.org/2001/XMLSchema#string

Elie Azoulay

http://www.w3.org/2001/XMLSchema#string

Eric Rondeau

http://www.w3.org/2001/XMLSchema#string

French Reference Center for Thrombotic Microangiopathies

http://www.w3.org/2001/XMLSchema#string

Jacques Pourrat

http://www.w3.org/2001/XMLSchema#string

P2860

Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura

Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura

Stepwise selection in small data sets: a simulation study of bias in logistic regression analysis.

Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases.

Changes in health and disease of the metalloprotease that cleaves von Willebrand factor.

Predicting response to plasma exchange in patients with thrombotic thrombocytopenic purpura with measurement of vWF-cleaving protease activity.

Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura.

High-dose plasma infusion versus plasma exchange as early treatment of thrombotic thrombocytopenic purpura/hemolytic-uremic syndrome.

ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients.

The Japanese experience with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome.

P304

e10208

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0010208

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

Agnès Veyradier

Michael Schwarzinger

P577

2010-04-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

43535608

http://www.w3.org/2001/XMLSchema#string

P698

20436664

http://www.w3.org/2001/XMLSchema#string

P921

P932

2859048

http://www.w3.org/2001/XMLSchema#string